Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Daniele Laszlò et al.|Journal of Clinical Oncology|2015Cited by 63
Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Blood|2013Cited by 13
Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.Daniele Laszlò, Giovanni Martinelli, Cristina Rabascio et al.|Blood|2007Cited by 4
Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Blood|2018Cited by 1